Peptide Library

Human study PLS-00001

Phase II trial of PL 14736 (BPC-157) enema in mild-to-moderate ulcerative colitis

Randomized controlled trial · Not reported participants enrolled

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Ruenzi M, et al. A Multicenter, Randomized, Double Blind, Placebo-Controlled Phase II Study of PL 14736 Enema in the Treatment of Mild-to-Moderate Ulcerative Colitis. Gastroenterology. 2005;128:A584 (meeting abstract).conference abstract

Design and participants

Design
Randomized controlled trial
Population
Patients with mild-to-moderate ulcerative colitis
Conditions
Ulcerative colitis
Setting
Multicenter
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

  • PL 14736 enema (intervention) · bpc-157 · PL 14736 (BPC-157) given as an enema · rectal (enema) · Not reported assigned
  • Placebo enema (comparator) · Placebo · placebo · rectal (enema) · Not reported assigned

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

  • abstract only: Only a bibliographic citation of a meeting abstract is available. There is no abstract text, so methods, sample size, outcomes and results cannot be assessed.
  • selective reporting: No results, outcomes or adverse events are reported in the record. Nor is there any indication of full publication or registration, so reporting completeness cannot be verified.
  • small or imprecise: Sample size and arm sizes are not stated in the record, so the precision of any findings cannot be judged.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Where each value comes from

  • arms: EXTERNAL report-1, citation (study title within citation) · extracted by AI (automated, not verified by a person) · abstract only
  • design: EXTERNAL report-1, citation (study title within citation) · extracted by AI (automated, not verified by a person) · abstract only
  • limitations: EXTERNAL report-1, citation (meeting abstract designation in citation) · extracted by AI (automated, not verified by a person) · abstract only
  • population: EXTERNAL report-1, citation (study title within citation) · extracted by AI (automated, not verified by a person) · abstract only

  • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).